Premium
SWATH‐Proteomics of Ibrutinib's Action in Myeloid Leukemia Initiating Mutated G‐CSFR Signaling
Author(s) -
Dwivedi Pankaj,
Chutipongtanate Somchai,
Muench David E.,
Azam Mohammad,
Grimes Harry Leighton,
Greis Kenneth D.
Publication year - 2020
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.201900144
Subject(s) - ibrutinib , bruton's tyrosine kinase , proteomics , leukemia , myeloid leukemia , cancer research , signal transduction , biology , computational biology , tyrosine kinase , bioinformatics , immunology , microbiology and biotechnology , genetics , gene , chronic lymphocytic leukemia
Purpose To evaluate cellular protein changes in response to treatment with an approved drug, ibrutinib, in cells expressing normal or mutated granulocyte‐colony stimulating factor receptor (G‐CSFR). G‐CSFR mutations are associated with some hematological malignancies. Previous studies show the efficacy of ibrutinib (a Bruton's tyrosine kinase inhibitor) in mutated G‐CSFR leukemia models but do not address broader signaling mechanisms. Experimental Design A label‐free quantitative proteomics workflow to evaluate the cellular effects of ibrutinib treatment is established. This includes three biological replicates of normal and mutated G‐CSFR expressed in a mouse progenitor cell (32D cell line) with and without ibrutinib treatment. Results The proteomics dataset shows about 1000 unique proteins quantified with nearly 400 significant changes ( p value < 0.05), suggesting a highly dynamic network of cellular signaling in response to ibrutinib. Importantly, the dataset is very robust with coefficients of variation for quantitation at 13.0–20.4% resulting in dramatic patterns of protein differences among the groups. Conclusions and Clinical Relevance This robust dataset is available for further mining, hypothesis generation, and testing. A detailed understanding of the restructuring of the proteomics signaling cascades by ibrutinib in leukemia biology will provide new avenues to explore its use for other related malignancies.